https://scholars.lib.ntu.edu.tw/handle/123456789/633101
標題: | Chronic hepatitis B with concurrent metabolic dys-function-associated fatty liver disease: Challenges and perspectives | 作者: | SHANG-CHIN HUANG CHUN-JEN LIU |
關鍵字: | Fatty liver | Hepatitis B virus | Hepatocellular carcinoma | Metabolic syndrome | Non-alcoholic fatty liver disease | 公開日期: | 1-四月-2023 | 出版社: | KOREAN ASSOC STUDY LIVER | 卷: | 29 | 期: | 2 | 起(迄)頁: | 320 | 來源出版物: | Clinical and Molecular Hepatology | 摘要: | The prevalence of metabolic dysfunction-associated fatty liver disease (MAFLD) has increased among the general population and chronic hepatitis B (CHB) patients worldwide. Although fatty liver disease is a well-known risk factor for adverse liver outcomes like cirrhosis and hepatocellular carcinoma, its interactions with the hepatitis B virus (HBV) and clinical impacts seem complex. The presence of hepatic steatosis may suppress HBV viral activity, potentially leading to attenuated liver injury. In contrast, the associated co-morbidities like diabetes mellitus or obesity may increase the risk of developing adverse liver outcomes. These findings implicate that components of MAFLD may have diverse effects on the clinical manifestations of CHB. To this end, a clinical strategy is proposed for managing patients with concurrent CHB and MAFLD. This review article discusses the updated evidence regarding disease prevalence, interactions between steatosis and HBV, clinical impacts, and management strategies, aiming at optimizing holistic health care in the CHB population. (Clin Mol Hepatol 2023;29:320-331). |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/633101 | ISSN: | 22872728 | DOI: | 10.3350/cmh.2022.0422 |
顯示於: | 臨床醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。